Bonus BioGroup Income Statement

Financials in millions ILS. Fiscal year is January - December.

Millions ILS. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2020 - 2016
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	2020 - 2016
Selling, General & Admin	10.53	10.23	11.18	15.74	43.94	Upgrade
Research & Development	13.23	17.61	18.61	21.31	20.79	Upgrade
Operating Expenses	23.76	27.84	29.79	37.05	64.74	Upgrade
Operating Income	-23.76	-27.84	-29.79	-37.05	-64.74	Upgrade
Interest Expense	-0.69	-0.78	-0.85	-0.89	-0.57	Upgrade
Interest & Investment Income	0.04	0.54	1.64	0.29	0.16	Upgrade
Currency Exchange Gain (Loss)	-0.08	0.29	0.5	6.98	-3.93	Upgrade
Other Non Operating Income (Expenses)	-0	-0.04	-0.03	-8.04	-21.01	Upgrade
Pretax Income	-24.49	-27.83	-28.53	-38.7	-90.08	Upgrade
Net Income	-24.49	-27.83	-28.53	-38.7	-90.08	Upgrade
Net Income to Common	-24.49	-27.83	-28.53	-38.7	-90.08	Upgrade
Shares Outstanding (Basic)	1,168	1,168	1,168	1,168	1,154	Upgrade
Shares Outstanding (Diluted)	1,168	1,168	1,168	1,168	1,154	Upgrade
Shares Change (YoY)	-	-	-	1.20%	15.52%	Upgrade
EPS (Basic)	-0.02	-0.02	-0.02	-0.03	-0.08	Upgrade
EPS (Diluted)	-0.02	-0.02	-0.02	-0.03	-0.08	Upgrade
Free Cash Flow	-14.95	-21.72	-27.22	-35.2	-45.65	Upgrade
Free Cash Flow Per Share	-0.01	-0.02	-0.02	-0.03	-0.04	Upgrade
EBITDA	-22.22	-26.2	-28.14	-34.38	-63.26	Upgrade
D&A For EBITDA	1.54	1.63	1.65	2.66	1.48	Upgrade
EBIT	-23.76	-27.84	-29.79	-37.05	-64.74	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.